Chinese herbal medicine Shufeng Jiedu capsule for patients with mild to moderate coronavirus disease 2019 (COVID-19): A randomized double-blind placebo-controlled clinical trial

Department of Science and Technology of Anhui Province0 个研究点目标入组 407 人开始时间: 2022年5月3日最近更新: 2024年7月8日

适应症

试验速览

2024 Results article in https://pubmed.ncbi.nlm.nih.gov/38863976/ (added 25/06/2024)

•1. Meet the mild and common diagnostic criteria for COVID-19;
•2. The time interval between symptom onset and random enrollment was less than 3 days;
•3. Adults (=18 and =75 years);
•4. Agree to participate in this study and accept random grouping;
•5. Those who have signed informed consent and are not currently participating in other clinical trials of traditional Chinese medicine for COVID-19

•1 Female patients in pregnancy and lactation;
•2 Patients with a history of allergy to the test drug ingredients;
•3. As judged by the investigator, or patients with acute episodes, cognitive insufficiency, or severe diarrhea (resulting in electrolyte disturbances and dehydration);
•4. Continuous use of traditional Chinese medicine (tripartite and three-drug treatment) for COVID-19 within 3 days before enrollment;
•5. Patients who are also participating in other clinical trials.

发起方

Department of Science and Technology of Anhui Province